All In MedTech

Device Trial Radar · NCT04396860

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 159 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

159

Actual

Start

Sep 1, 2020

Primary completion

Jan 13, 2023

Study completion Dec 23, 2025

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
May 21, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.

Conditions

  • Gliosarcoma
  • MGMT-Unmethylated Glioblastoma

Interventions

  • Contrast-enhanced Magnetic Resonance ImagingProcedure

    Undergo contrast-enhanced brain MRI

  • IpilimumabBiological

    Given IV

  • NivolumabBiological

    Given IV

  • NovoTTF-100A DeviceDevice

    Wear Optune device

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo radiation therapy

  • TemozolomideDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) (Phase II)Time frame: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
  2. Overall Survival (OS) (Phase III)Time frame: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.

Locations

285 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

282 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.